<DOC>
	<DOCNO>NCT01513083</DOCNO>
	<brief_summary>This open-label , parallel group study evaluate pharmacokinetics safety trastuzumab emtansine patient HER2-positive metastatic breast cancer normal reduce hepatic function . Patients receive trastuzumab emtansine intravenously Day 1 3-week cycle . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine Patients With HER2-Positive Metastatic Breast Cancer Normal Reduced Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically document invasive metastatic breast cancer Human epidermal growth factor receptor 2 ( HER2 ) positive disease Adequate bone marrow organ function ( hepatic dysfunction allow protocol ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Left ventricular ejection fraction &gt; /=50 % Normal hepatic function , mild moderate hepatic impairment ( ChildPugh Class A B ) History Grade &gt; /=3 infusion reaction , hypersensitivity reaction , pneumonitis response trastuzumab Investigational therapy anticancer therapy &lt; /=28 day first study treatment Previous treatment trastuzumab emtansine Brain metastasis untreated symptomatic require therapy control symptom radiation , surgery therapy control symptom brain metastasis within 1 month first study treatment History malignancy within last 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , cancer similar outcome mention Current peripheral neuropathy Grade &gt; /=2 ChildPugh Class C hepatic impairment Encephalopathy &gt; /= Grade 2 For patient normal hepatic function : history drug alcohol addiction history hepatitis B and/or hepatitis C Active hepatitis A , B and/or C Current unstable ventricular arrhythmia require treatment History symptomatic CHF ( NYHA Classes IIIV ) History myocardial infarction unstable angina within 6 month enrollment History decrease LVEF &lt; 40 % symptomatic CHF previous trastuzumab treatment Pregnant lactate woman Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>